Monoclonal Antibodies for Treatment of COVID-19: An Updated Review of Current Evidence
Article Sidebar
Submitted
16 December 2023
Published
30 November 2024
Keywords:
-
SARS-CoV-2, Bamlanivimab, AstraZeneca, Wuhan
Abstract
The emergence of COVID-19 in December 2019 spurred a global effort to develop effective medical interventions. Therapeutic monoclonal antibodies (mAbs) have emerged as a promising strategy to combat the SARS-CoV-2 virus. Several mAbs targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein have received Emergency Use Authorization (EUA) for treating mild to moderate COVID-19. Additionally, human mAbs and hyperimmune plasma derived from recovered COVID-19 patients have been explored as potential therapeutic options. This review delves into the potential of mAbs for the diagnosis and treatment of COVID-19 infection. We discuss the mechanisms of action of mAbs, as well as their advantages and limitations. Furthermore, we explore the ongoing research and development efforts to optimize mAb-based therapies for COVID-19.
Full text article
Generated from XML file
References
1. Chauhan S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomed J. 2020;43(4):334-40. DOI: 10.1016/j.bj.2020.05.023; PMCID: PMC7263230; PMID: 32788071
2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54. DOI: 10.1038/s41579-020-00459-7; PMCID: PMC7537588; PMID: 33024307
3. Bai C, Zhong Q, Gao GF. Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. 2022;65(2):280-94. DOI: 10.1007/s11427-021-1964-4; PMCID: PMC8362648; PMID: 34387838
4. Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2020;50:102125. DOI: 10.1016/j.scr.2020.102125; PMCID: PMC7737530; PMID: 33341604
5. Torrente-López A, Hermosilla J, Navas N, Cuadros-Rodríguez L, Cabeza J, Salmerón-García A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines. 2021;9(6):557. DOI: 10.3390/vaccines9060557; PMCID: PMC8229508; PMID: 34073559
6. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. DOI: 10.1002/prp2.535; PMCID: PMC6923804; PMID: 31859459
7. Jo EK. Interplay between host and pathogen: immune defense and beyond. Exp Mol Med. 2019;51(12):1-3. DOI: 10.1038/s12276-019-0281-8; PMCID: PMC6906370; PMID: 31827066
8. Singh M, de Wit E. Antiviral agents for the treatment of COVID-19: Progress and challenges. Cell Rep Med. 2022;3(3):100549. DOI: 10.1016/j.xcrm.2022.100549; PMCID: PMC8831133; PMID: 35474740
9. Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449-75. DOI: 10.1038/s41573-023-00672-y; PMCID: PMC10113999; PMID: 37076602
10. McManus D, Davis MW, Ortiz A, Britto-Leon C, Cruz CSD, Topal JE. Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia. Clin Chest Med. 2023;44(2):299-319. DOI: 10.1016/j.ccm.2022.11.009; PMCID: PMC9678826; PMID: 37085221
11. Adibzadeh S, Amiri S, Nia GE, Taleghani MR, Bijarpas ZK, Maserat N, et al. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Rep. 2022;27:101619. DOI: 10.1016/j.genrep.2022.101619; PMCID: PMC9066810; PMID: 35530725
12. Ren Z, Shen C, Peng J. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Viruses. 2023;15(6):1297. DOI: 10.3390/v15061297; PMCID: PMC10302031; PMID: 37376597
13. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-93. DOI: 10.1038/s41577-021-00542-x; PMCID: PMC8054133; PMID: 33875867
14. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 2022;21(9):676-96. DOI: 10.1038/s41573-022-00495-3; PMCID: PMC9207876; PMID: 35725925
15. Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 2021;42(12):1143-58. DOI: 10.1016/j.it.2021.10.008; PMID: 34743921
16. Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs. 2022;31(1):41-58. DOI: 10.1080/13543784.2022.2030310; PMCID: PMC8862171; PMID: 35164631
17. Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JKC, Frooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013;31(12):1553-9. DOI: 10.1016/j.vaccine.2013.01.025; PMCID: PMC7115371; PMID: 23370150
18. Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576-88. DOI: 10.1002/psp4.12224; PMCID: PMC5613179; PMID: 28653357
19. Hooks MA, Wade CS, Millikan Jr WJ. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11(1):26-37. PMID: 1902291
20. Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies. 2019;8(4):55. DOI: 10.3390/antib8040055; PMCID: PMC6963682; PMID: 31816964
21. Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019;10: 2040622319838443. DOI: 10.1177/2040622319838443; PMCID: PMC6435871; PMID: 30937157
22. Ariga S. History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. J Clin Med. 2023;12(10):3391. DOI: 10.3390/jcm12103391; PMCID: PMC10219249; PMID: 37240498
23. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. DOI: 10.1186/s12929-019-0592-z; PMCID: PMC6939334; PMID: 31894001
24. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(1):165878. DOI: 10.1016/j.bbadis.2020.165878; PMCID: PMC7293463; PMID: 32544429
25. Nejat R, Torshizi MF, Najafi DJ. S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. Vaccines. 2023;11(2):204. DOI: 10.3390/vaccines11020204; PMCID: PMC9968219; PMID: 36851081
26. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3-20. DOI: 10.1038/s41580-021-00418-x; PMCID: PMC8491763; PMID: 34611326
27. Beyerstedt S, Casaro EB, Rangel EB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905-19. DOI: 10.1007/s10096-020-04138-6; PMCID: PMC7778857; PMID: 33389262
28. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22(11):e311-26. DOI: 10.1016/s1473-3099(22)00311-5; PMCID: PMC9255948; PMID: 35803289
29. Romero A, Laurent C, Lebourg L, Lemée V, Hanoy M, Roy FL, et al. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses. 2024;16(3):381. DOI: 10.3390/v16030381; PMCID: PMC10975193; PMID: 38543747
30. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1. DOI: 10.1186/s12929-021-00784-w; PMCID: PMC8724751; PMID: 34983527
31. Izadi A, Nordenfelt P. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies. Trends Immunol. 2024;45(8):609-24. DOI: 10.1016/j.it.2024.06.003; PMID: 39034185
32. Destache CJ, Aurit SJ, Schmidt D, Erkes LP, Tierney M, Vivekanandan R. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design. Pharmacotherapy. 2021;41(9):743-7. DOI: 10.1002/phar.2613; PMCID: PMC8441667; PMID: 34328670
33. Chen P, Datta G, Li YG, Chien J, Price K, Chigutsa E, et al. First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. Clin Pharmacol Ther. 2021;110(6):1467-77. DOI: 10.1002/cpt.2405; PMCID: PMC8653186; PMID: 34455583
34. Cui Z, Wang H, Zou H, Li L, Zhang Y, Chen W. Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis. J Thorac Dis. 2024;16(6):3606-22. DOI: 10.21037/jtd-23-1604; PMCID: PMC11228754; PMID: 38983147
35. Filippo SS, Crovetto B, Bucek J, Nahass RG, Milano M, Brunetti L. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis. Open Forum Infect Dis. 2022;9(4):ofac080. DOI: 10.1093/ofid/ofac080; PMCID: PMC8923391; PMID: 35299987
36. Quiros-Roldan E, Amadasi S, Zanella I, Antoni MD, Storti S, Tiecco G, et al. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Pharmaceuticals. 2021;14(12):1272. DOI: 10.3390/ph14121272; PMCID: PMC8707981; PMID: 34959672
37. Deeks ED. Casirivimab/Imdevimab: First Approval. Drugs. 2021;81(17):2047-55. DOI: 10.1007/s40265-021-01620-z; PMCID: PMC8556815; PMID: 34716907
38. O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022;327(5):432-41. DOI: 10.1001/jama.2021.24939; PMCID: PMC8808333; PMID: 35029629
39. Krone M, Wagenhäuser I, Knies K, Hofmann D, Engels G, Taurines R, et al. Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents. J Infect. 2023;86(3):256-308. DOI: 10.1016/j.jinf.2022.12.017; PMCID: PMC9767879; PMID: 36565725
40. Sakurai A, Marshall S, Ogasawara T, Ogasawara T, Aoka Y, Sakura H, et al. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan. J Infect Chemother. 2022;28(7):943-7. DOI: 10.1016/j.jiac.2022.03.029; PMCID: PMC8986486; PMID: 35414436
41. Doggrell SA. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? Expert Opin Biol Ther. 2021;21(11):1359-62. DOI: 10.1080/14712598.2021.1985458; PMCID: PMC8500303; PMID: 34555986
42. Vena A, Cenderello G, Balletto E, Mezzogori L, Barbone AS, Berruti M, et al. Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region. J Clin Med. 2021;10(2):4682. DOI: 10.3390/jcm10204682; PMCID: PMC8538905; PMID: 34682805
43. Chen P, Behre G, Hebert C, Kumar P, Macpherson LF, Graham-Clarke PL, et al. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial. Open Forum Infect Dis. 2022;9(5):ofac172. DOI: 10.1093/ofid/ofac172; PMCID: PMC9045956; PMID: 35493124
44. Plichta J, Kuna P, Panek M. Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents. COVID. 2022;2(5):599-620. DOI: 10.3390/covid2050045
45. Pinna SM, Lupia T, Scabini S, Vita D, De Benedetto I, Gaviraghi A, et al. Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm? Int Immunopharmacol. 2021;101(Pt A):108200. DOI: 10.1016/j.intimp.2021.108200; PMCID: PMC8479899; PMID: 34607231
46. Focosi D, Casadevall A, Franchini M, Maggi F. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses. 2024;16(2):217. DOI: 10.3390/v16020217; PMCID: PMC10891757; PMID: 38399991
47. Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci DR, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022;327(13):1236-46. DOI: 10.1001/jama.2022.2832; PMCID: PMC8922199; PMID: 35285853
48. Griffin D, McNeil C, Okusa J, Berrent D, Guo Y, Daugherty SE. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. BMJ Open. 2023;13(8):e069247. DOI: 10.1136/bmjopen-2022-069247; PMCID: PMC10414114; PMID: 37553188
49. Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, et al. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. J Pediatric Infect Dis Soc. 2022;11(5):177-85. DOI: 10.1093/jpids/piab124; PMCID: PMC8903349; PMID: 35107571
50. Sarrell BA, Bloch K, El Chediak A, Kumm K, Tracy K, Forbes RC, et al. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022;24(1):e13759. DOI: 10.1111/tid.13759; PMCID: PMC8646855; PMID: 34787345
51. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331. DOI: 10.1093/ofid/ofab331; PMCID: PMC8314951; PMID: 34327256
52. Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086-108. DOI: 10.1016/j.cell.2021.05.005; PMCID: PMC8152891; PMID: 34087172
53. McCreary EK, Bariola JR, Wadas RJ, Shovel JA, Wisniewski MK, Adam M, et al. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Netw Open. 2022;5(4):e226920. DOI: 10.1001/jamanetworkopen.2022.6920; PMCID: PMC9006104; PMID: 35412625
54. Isa F, Ortiz AMG, Meyer J, Hamilton JD, Olenchock BA, Brackin T, et al. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial. Lancet Infect Dis. 2024;S1473-3099(24)00421-3. DOI: 10.1016/s1473-3099(24)00421-3; PMID: 39236733
55. Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, et al. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev. 2022;8(8):CD01521. DOI: 10.1002/14651858.cd015021; PMCID: PMC9361430; PMID: 35943061
56. Smati S, Tramunt B, Wargny M, Caussy C, Gaborit B, Vatier C, et al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. Diabetes Obes Metab. 2021;23(2):391-403. DOI: 10.1111/dom.14228; PMCID: PMC7675375; PMID: 33051976
57. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-9. DOI: 10.1038/s41401-020-0485-4; PMCID: PMC7396720; PMID: 32747721
58. Suvarnapathaki S, Chauhan D, Nguyen A, Ramalingam M, Camci-Unal G. Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. Ann Biomed Eng. 2022;50(12):1734-49. DOI: 10.1007/s10439-022-03094-w; PMCID: PMC9581451; PMID: 36261668
59. Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi A, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In: Andronescu E, Grumezescu AM, editors. Nanostructures for Drug Delivery. Amsterdam: Elsevier; 2017. DOI: 10.1016/B978-0-323-46143-6.00025-7; PMCID: PMC7151974
60. Zhou D, Zhou R, Chen Z. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunother Adv. 2021;2(1):ltab027. DOI: 10.1093/immadv/ltab027; PMCID: PMC8755319; PMID: 35915816
61. Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021;19(1):159. DOI: 10.1186/s43141-021-00264-6; PMCID: PMC8521504; PMID: 34661773
62. Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020;9(3):34. DOI: 10.3390/antib9030034; PMCID: PMC7551545; PMID: 32698317
63. Andrews NP, Boeckman JX, Manning CF, Nguyen JT, Bechtold H, Dumitras C, et al. A toolbox of IgG subclass-switched recombinant monoclonal antibodies for enhanced multiplex immunolabeling of brain. Elife. 2019;8:e43322. DOI: 10.7554/elife.43322; PMCID: PMC6377228; PMID: 30667360
64. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290-5. DOI: 10.1038/s41586-020-2349-y; PMID: 32422645
65. Shrestha J, Sherchan R. Bamlanivimab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. NBKID: NBK576376
66. Tai YL, Lee MD, Chi H, Chiu NC, Lei WT, Weng SL, et al. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. PeerJ. 2023;11:e15344. DOI: 10.7717/peerj.15344; PMCID: PMC10174063; PMID: 37180576
67. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines. 2021;10(1):62. DOI: 10.3390/vaccines10010062; PMCID: PMC8779282; PMID: 35062723
68. Esposito S, Amirthalingam G, Bassetti M, Blasi F, De Rosa FG, Halasa NB, et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front Immunol. 2023;14:1162342. DOI: 10.3389/fimmu.2023.1162342; PMCID: PMC10226646; PMID: 37256125
69. Baldo BA. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies. 2022;11(1):17. DOI: 10.3390/antib11010017; PMCID: PMC8944650; PMID: 35323191
70. Gopalaswamy R, Aravindhan V, Subbian S. The Ambivalence of Post COVID-19 Vaccination Responses in Humans. Biomolecules. 2024;14(10):1320. DOI: 10.3390/biom14101320; PMCID: PMC11506738; PMID: 39456253
71. Chen Z, Zhang P, Matsuoka Y, Tsybovsky Y, West K, Santos C, et al. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. Cell Rep. 2022;41(5):111528. DOI: 10.1016/j.celrep.2022.111528; PMCID: PMC9554601; PMID: 36302375
72. Sapir T, Averch Z, Lerman B, Bodzin A, Fishman Y, Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. Int J Mol Sci. 2022;23(15):8606. DOI: 10.3390/ijms23158606; PMCID: PMC9369212; PMID: 35955740
73. Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, COVID-19 Genomics UK (COG-UK) Consortium, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112-24. DOI: 10.1038/s41579-022-00809-7; PMCID: PMC9616429; PMID: 36307535
74. Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci Transl Med. 2021;13(616):eabj5413. DOI: 10.1126/scitranslmed.abj5413; PMCID: PMC8651051; PMID: 34519517
75. Yilmaz O, Torres T. Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis. Dermatol Ther. 2024;14(9):2393-406. DOI: 10.1007/s13555-024-01253-6; PMCID: PMC11393227; PMID: 39147994
76. Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9(3):e13952. DOI: 10.1016/j.heliyon.2023.e13952; PMCID: PMC9946785; PMID: 36855648
77. Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26(10):2367-76. DOI: 10.1016/j.drudis.2021.05.008; PMCID: PMC8139175; PMID: 34023496
78. Wang R, Guo J, Lu J, Du P, Zhang J, Yu Y, et al. A potential broad-spectrum neutralizing antibody against Betacoronavirus. J Med Virol. 2023;95(12):e29252. DOI: 10.1002/jmv.29252; PMID: 38078658
79. Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, et al. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Sci Rep. 2021;11(1):11046. DOI: 10.1038/s41598-021-90348-7; PMCID: PMC8155001; PMID: 34040046
80. Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100-17. DOI: 10.1016/j.addr.2020.12.004; PMCID: PMC7833882; PMID: 33309815
81. Akram F, Ali AM, Akhtar MT, Fatima T, Shabbir I, Haq IU. The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review. Bioorg Med Chem. 2024;117:118010. DOI: 10.1016/j.bmc.2024.118010; PMID: 39586174
82. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1)93. DOI: 10.1038/s41392-022-00947-7; PMCID: PMC8941077; PMID: 35318309
2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54. DOI: 10.1038/s41579-020-00459-7; PMCID: PMC7537588; PMID: 33024307
3. Bai C, Zhong Q, Gao GF. Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. 2022;65(2):280-94. DOI: 10.1007/s11427-021-1964-4; PMCID: PMC8362648; PMID: 34387838
4. Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2020;50:102125. DOI: 10.1016/j.scr.2020.102125; PMCID: PMC7737530; PMID: 33341604
5. Torrente-López A, Hermosilla J, Navas N, Cuadros-Rodríguez L, Cabeza J, Salmerón-García A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines. 2021;9(6):557. DOI: 10.3390/vaccines9060557; PMCID: PMC8229508; PMID: 34073559
6. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. DOI: 10.1002/prp2.535; PMCID: PMC6923804; PMID: 31859459
7. Jo EK. Interplay between host and pathogen: immune defense and beyond. Exp Mol Med. 2019;51(12):1-3. DOI: 10.1038/s12276-019-0281-8; PMCID: PMC6906370; PMID: 31827066
8. Singh M, de Wit E. Antiviral agents for the treatment of COVID-19: Progress and challenges. Cell Rep Med. 2022;3(3):100549. DOI: 10.1016/j.xcrm.2022.100549; PMCID: PMC8831133; PMID: 35474740
9. Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449-75. DOI: 10.1038/s41573-023-00672-y; PMCID: PMC10113999; PMID: 37076602
10. McManus D, Davis MW, Ortiz A, Britto-Leon C, Cruz CSD, Topal JE. Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia. Clin Chest Med. 2023;44(2):299-319. DOI: 10.1016/j.ccm.2022.11.009; PMCID: PMC9678826; PMID: 37085221
11. Adibzadeh S, Amiri S, Nia GE, Taleghani MR, Bijarpas ZK, Maserat N, et al. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Rep. 2022;27:101619. DOI: 10.1016/j.genrep.2022.101619; PMCID: PMC9066810; PMID: 35530725
12. Ren Z, Shen C, Peng J. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Viruses. 2023;15(6):1297. DOI: 10.3390/v15061297; PMCID: PMC10302031; PMID: 37376597
13. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-93. DOI: 10.1038/s41577-021-00542-x; PMCID: PMC8054133; PMID: 33875867
14. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 2022;21(9):676-96. DOI: 10.1038/s41573-022-00495-3; PMCID: PMC9207876; PMID: 35725925
15. Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 2021;42(12):1143-58. DOI: 10.1016/j.it.2021.10.008; PMID: 34743921
16. Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs. 2022;31(1):41-58. DOI: 10.1080/13543784.2022.2030310; PMCID: PMC8862171; PMID: 35164631
17. Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JKC, Frooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013;31(12):1553-9. DOI: 10.1016/j.vaccine.2013.01.025; PMCID: PMC7115371; PMID: 23370150
18. Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576-88. DOI: 10.1002/psp4.12224; PMCID: PMC5613179; PMID: 28653357
19. Hooks MA, Wade CS, Millikan Jr WJ. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11(1):26-37. PMID: 1902291
20. Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies. 2019;8(4):55. DOI: 10.3390/antib8040055; PMCID: PMC6963682; PMID: 31816964
21. Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019;10: 2040622319838443. DOI: 10.1177/2040622319838443; PMCID: PMC6435871; PMID: 30937157
22. Ariga S. History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. J Clin Med. 2023;12(10):3391. DOI: 10.3390/jcm12103391; PMCID: PMC10219249; PMID: 37240498
23. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. DOI: 10.1186/s12929-019-0592-z; PMCID: PMC6939334; PMID: 31894001
24. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(1):165878. DOI: 10.1016/j.bbadis.2020.165878; PMCID: PMC7293463; PMID: 32544429
25. Nejat R, Torshizi MF, Najafi DJ. S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. Vaccines. 2023;11(2):204. DOI: 10.3390/vaccines11020204; PMCID: PMC9968219; PMID: 36851081
26. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3-20. DOI: 10.1038/s41580-021-00418-x; PMCID: PMC8491763; PMID: 34611326
27. Beyerstedt S, Casaro EB, Rangel EB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905-19. DOI: 10.1007/s10096-020-04138-6; PMCID: PMC7778857; PMID: 33389262
28. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22(11):e311-26. DOI: 10.1016/s1473-3099(22)00311-5; PMCID: PMC9255948; PMID: 35803289
29. Romero A, Laurent C, Lebourg L, Lemée V, Hanoy M, Roy FL, et al. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses. 2024;16(3):381. DOI: 10.3390/v16030381; PMCID: PMC10975193; PMID: 38543747
30. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1. DOI: 10.1186/s12929-021-00784-w; PMCID: PMC8724751; PMID: 34983527
31. Izadi A, Nordenfelt P. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies. Trends Immunol. 2024;45(8):609-24. DOI: 10.1016/j.it.2024.06.003; PMID: 39034185
32. Destache CJ, Aurit SJ, Schmidt D, Erkes LP, Tierney M, Vivekanandan R. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design. Pharmacotherapy. 2021;41(9):743-7. DOI: 10.1002/phar.2613; PMCID: PMC8441667; PMID: 34328670
33. Chen P, Datta G, Li YG, Chien J, Price K, Chigutsa E, et al. First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. Clin Pharmacol Ther. 2021;110(6):1467-77. DOI: 10.1002/cpt.2405; PMCID: PMC8653186; PMID: 34455583
34. Cui Z, Wang H, Zou H, Li L, Zhang Y, Chen W. Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis. J Thorac Dis. 2024;16(6):3606-22. DOI: 10.21037/jtd-23-1604; PMCID: PMC11228754; PMID: 38983147
35. Filippo SS, Crovetto B, Bucek J, Nahass RG, Milano M, Brunetti L. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis. Open Forum Infect Dis. 2022;9(4):ofac080. DOI: 10.1093/ofid/ofac080; PMCID: PMC8923391; PMID: 35299987
36. Quiros-Roldan E, Amadasi S, Zanella I, Antoni MD, Storti S, Tiecco G, et al. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Pharmaceuticals. 2021;14(12):1272. DOI: 10.3390/ph14121272; PMCID: PMC8707981; PMID: 34959672
37. Deeks ED. Casirivimab/Imdevimab: First Approval. Drugs. 2021;81(17):2047-55. DOI: 10.1007/s40265-021-01620-z; PMCID: PMC8556815; PMID: 34716907
38. O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022;327(5):432-41. DOI: 10.1001/jama.2021.24939; PMCID: PMC8808333; PMID: 35029629
39. Krone M, Wagenhäuser I, Knies K, Hofmann D, Engels G, Taurines R, et al. Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents. J Infect. 2023;86(3):256-308. DOI: 10.1016/j.jinf.2022.12.017; PMCID: PMC9767879; PMID: 36565725
40. Sakurai A, Marshall S, Ogasawara T, Ogasawara T, Aoka Y, Sakura H, et al. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan. J Infect Chemother. 2022;28(7):943-7. DOI: 10.1016/j.jiac.2022.03.029; PMCID: PMC8986486; PMID: 35414436
41. Doggrell SA. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? Expert Opin Biol Ther. 2021;21(11):1359-62. DOI: 10.1080/14712598.2021.1985458; PMCID: PMC8500303; PMID: 34555986
42. Vena A, Cenderello G, Balletto E, Mezzogori L, Barbone AS, Berruti M, et al. Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region. J Clin Med. 2021;10(2):4682. DOI: 10.3390/jcm10204682; PMCID: PMC8538905; PMID: 34682805
43. Chen P, Behre G, Hebert C, Kumar P, Macpherson LF, Graham-Clarke PL, et al. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial. Open Forum Infect Dis. 2022;9(5):ofac172. DOI: 10.1093/ofid/ofac172; PMCID: PMC9045956; PMID: 35493124
44. Plichta J, Kuna P, Panek M. Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents. COVID. 2022;2(5):599-620. DOI: 10.3390/covid2050045
45. Pinna SM, Lupia T, Scabini S, Vita D, De Benedetto I, Gaviraghi A, et al. Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm? Int Immunopharmacol. 2021;101(Pt A):108200. DOI: 10.1016/j.intimp.2021.108200; PMCID: PMC8479899; PMID: 34607231
46. Focosi D, Casadevall A, Franchini M, Maggi F. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses. 2024;16(2):217. DOI: 10.3390/v16020217; PMCID: PMC10891757; PMID: 38399991
47. Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci DR, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022;327(13):1236-46. DOI: 10.1001/jama.2022.2832; PMCID: PMC8922199; PMID: 35285853
48. Griffin D, McNeil C, Okusa J, Berrent D, Guo Y, Daugherty SE. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. BMJ Open. 2023;13(8):e069247. DOI: 10.1136/bmjopen-2022-069247; PMCID: PMC10414114; PMID: 37553188
49. Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, et al. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. J Pediatric Infect Dis Soc. 2022;11(5):177-85. DOI: 10.1093/jpids/piab124; PMCID: PMC8903349; PMID: 35107571
50. Sarrell BA, Bloch K, El Chediak A, Kumm K, Tracy K, Forbes RC, et al. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022;24(1):e13759. DOI: 10.1111/tid.13759; PMCID: PMC8646855; PMID: 34787345
51. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331. DOI: 10.1093/ofid/ofab331; PMCID: PMC8314951; PMID: 34327256
52. Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086-108. DOI: 10.1016/j.cell.2021.05.005; PMCID: PMC8152891; PMID: 34087172
53. McCreary EK, Bariola JR, Wadas RJ, Shovel JA, Wisniewski MK, Adam M, et al. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Netw Open. 2022;5(4):e226920. DOI: 10.1001/jamanetworkopen.2022.6920; PMCID: PMC9006104; PMID: 35412625
54. Isa F, Ortiz AMG, Meyer J, Hamilton JD, Olenchock BA, Brackin T, et al. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial. Lancet Infect Dis. 2024;S1473-3099(24)00421-3. DOI: 10.1016/s1473-3099(24)00421-3; PMID: 39236733
55. Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, et al. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev. 2022;8(8):CD01521. DOI: 10.1002/14651858.cd015021; PMCID: PMC9361430; PMID: 35943061
56. Smati S, Tramunt B, Wargny M, Caussy C, Gaborit B, Vatier C, et al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. Diabetes Obes Metab. 2021;23(2):391-403. DOI: 10.1111/dom.14228; PMCID: PMC7675375; PMID: 33051976
57. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-9. DOI: 10.1038/s41401-020-0485-4; PMCID: PMC7396720; PMID: 32747721
58. Suvarnapathaki S, Chauhan D, Nguyen A, Ramalingam M, Camci-Unal G. Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. Ann Biomed Eng. 2022;50(12):1734-49. DOI: 10.1007/s10439-022-03094-w; PMCID: PMC9581451; PMID: 36261668
59. Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi A, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In: Andronescu E, Grumezescu AM, editors. Nanostructures for Drug Delivery. Amsterdam: Elsevier; 2017. DOI: 10.1016/B978-0-323-46143-6.00025-7; PMCID: PMC7151974
60. Zhou D, Zhou R, Chen Z. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunother Adv. 2021;2(1):ltab027. DOI: 10.1093/immadv/ltab027; PMCID: PMC8755319; PMID: 35915816
61. Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021;19(1):159. DOI: 10.1186/s43141-021-00264-6; PMCID: PMC8521504; PMID: 34661773
62. Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020;9(3):34. DOI: 10.3390/antib9030034; PMCID: PMC7551545; PMID: 32698317
63. Andrews NP, Boeckman JX, Manning CF, Nguyen JT, Bechtold H, Dumitras C, et al. A toolbox of IgG subclass-switched recombinant monoclonal antibodies for enhanced multiplex immunolabeling of brain. Elife. 2019;8:e43322. DOI: 10.7554/elife.43322; PMCID: PMC6377228; PMID: 30667360
64. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290-5. DOI: 10.1038/s41586-020-2349-y; PMID: 32422645
65. Shrestha J, Sherchan R. Bamlanivimab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. NBKID: NBK576376
66. Tai YL, Lee MD, Chi H, Chiu NC, Lei WT, Weng SL, et al. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. PeerJ. 2023;11:e15344. DOI: 10.7717/peerj.15344; PMCID: PMC10174063; PMID: 37180576
67. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines. 2021;10(1):62. DOI: 10.3390/vaccines10010062; PMCID: PMC8779282; PMID: 35062723
68. Esposito S, Amirthalingam G, Bassetti M, Blasi F, De Rosa FG, Halasa NB, et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front Immunol. 2023;14:1162342. DOI: 10.3389/fimmu.2023.1162342; PMCID: PMC10226646; PMID: 37256125
69. Baldo BA. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies. 2022;11(1):17. DOI: 10.3390/antib11010017; PMCID: PMC8944650; PMID: 35323191
70. Gopalaswamy R, Aravindhan V, Subbian S. The Ambivalence of Post COVID-19 Vaccination Responses in Humans. Biomolecules. 2024;14(10):1320. DOI: 10.3390/biom14101320; PMCID: PMC11506738; PMID: 39456253
71. Chen Z, Zhang P, Matsuoka Y, Tsybovsky Y, West K, Santos C, et al. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. Cell Rep. 2022;41(5):111528. DOI: 10.1016/j.celrep.2022.111528; PMCID: PMC9554601; PMID: 36302375
72. Sapir T, Averch Z, Lerman B, Bodzin A, Fishman Y, Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. Int J Mol Sci. 2022;23(15):8606. DOI: 10.3390/ijms23158606; PMCID: PMC9369212; PMID: 35955740
73. Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, COVID-19 Genomics UK (COG-UK) Consortium, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112-24. DOI: 10.1038/s41579-022-00809-7; PMCID: PMC9616429; PMID: 36307535
74. Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci Transl Med. 2021;13(616):eabj5413. DOI: 10.1126/scitranslmed.abj5413; PMCID: PMC8651051; PMID: 34519517
75. Yilmaz O, Torres T. Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis. Dermatol Ther. 2024;14(9):2393-406. DOI: 10.1007/s13555-024-01253-6; PMCID: PMC11393227; PMID: 39147994
76. Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9(3):e13952. DOI: 10.1016/j.heliyon.2023.e13952; PMCID: PMC9946785; PMID: 36855648
77. Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26(10):2367-76. DOI: 10.1016/j.drudis.2021.05.008; PMCID: PMC8139175; PMID: 34023496
78. Wang R, Guo J, Lu J, Du P, Zhang J, Yu Y, et al. A potential broad-spectrum neutralizing antibody against Betacoronavirus. J Med Virol. 2023;95(12):e29252. DOI: 10.1002/jmv.29252; PMID: 38078658
79. Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, et al. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Sci Rep. 2021;11(1):11046. DOI: 10.1038/s41598-021-90348-7; PMCID: PMC8155001; PMID: 34040046
80. Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100-17. DOI: 10.1016/j.addr.2020.12.004; PMCID: PMC7833882; PMID: 33309815
81. Akram F, Ali AM, Akhtar MT, Fatima T, Shabbir I, Haq IU. The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review. Bioorg Med Chem. 2024;117:118010. DOI: 10.1016/j.bmc.2024.118010; PMID: 39586174
82. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1)93. DOI: 10.1038/s41392-022-00947-7; PMCID: PMC8941077; PMID: 35318309
Authors
1.
Nimesh S, Kumari P, Kumar R, Gosiya G, Quamuddin M, Ahmad MI. Monoclonal Antibodies for Treatment of COVID-19: An Updated Review of Current Evidence. Borneo J Pharm [Internet]. 2024Nov.30 [cited 2024Dec.12];7(4):342-56. Available from: https://journal.umpr.ac.id/index.php/bjop/article/view/6365
Copyright (c) 2024 Saurabh Nimesh, Pratibha Kumari, Rohit Kumar, Gosiya Gosiya, Md. Quamuddin, Md. Iftekhar Ahmad
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.
Article Details
